Sugi Predict

Sugi Predict / Compounds / SCHEMBL22345013

SCHEMBL22345013

SCHEMBL22345013

COC(=O)c1cc(OC)ccc1-c1ccc(OC)cc1C(=O)OC

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.80
▸ CYP1A2 P05177 2/20 0.80
▸ CYP2C19 P33261 2/20 0.80
▸ CYP2D6 P10635 1/20 0.80
▸ CYP2C9 P11712 1/20 0.80
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ NR4A2 P43354 1/20 0.54
▸ CA1 P00915 3/20 0.53
▸ CA2 P00918 3/20 0.53
▸ GLA P06280 2/20 0.49
▸ GAA P10253 2/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ MAPT P10636 3/20 0.49
▸ HTT P42858 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ RAB9A P51151 2/20 0.48
▸ CA7 P43166 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ CA12 O43570 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009450 1.00 KDM4E (0.80) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL29853687 0.93 KDM4E (0.71) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL26768656 0.91 KDM4E (0.69) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL5311021 0.86 KDM4E (0.82) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL26785965 0.86 KDM4E (0.61) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL29853731 0.86 KDM4E (0.61) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL382822 0.86 KDM4E (0.66) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL14063326 0.85 KDM4E (0.79) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL20430500 0.85 CYP1A2 (0.85) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL2949877 0.84 KDM4E (0.64) KDM4ECYP1A2CYP2C19CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473269-B2 Urolithin derivatives and methods of use thereof VANDRIA SA (CH) 2025-11-18 — — US disclosed
US-12358884-B2 Urolithin derivatives and methods of use thereof VANDRIA SA (CH) 2025-07-15 — — US disclosed
US-12351567-B2 Urolithin derivatives and methods of use thereof VANDRIA SA (CH) 2025-07-08 — — US disclosed
US-20240424006-A1 USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS VANDRIA SA (CH) 2024-12-26 — — US disclosed
US-20240158363-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF AMAZENTIS SA (CH) 2024-05-16 — — US disclosed
US-20240158364-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF AMAZENTIS SA (CH) 2024-05-16 — — US disclosed
US-20240158365-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF AMAZENTIS SA (CH) 2024-05-16 — — US disclosed
US-20240139149-A1 THERAPEUTIC USES OF UROLITHIN DERIVATIVES VANDRIA SA (CH) 2024-05-02 — — US disclosed
WO-2024025953-A2 THERAPEUTIC USES OF UROLITHIN DERIVATIVES VANDRIA SA (CH) 2024-02-01 — — WO disclosed
EP-4284781-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF Vandria SA (CH) 2023-12-06 — — EP disclosed
US-11820751-B2 Urolithin derivatives and methods of use thereof VANDRIA SA (CH) 2023-11-21 — — US disclosed
US-11820751-B2 Urolithin derivatives and methods of use thereof VANDRIA SA (CH) 2023-11-21 — — US disclosed
CN-117015530-A Urolithin derivatives and methods of use thereof 范徳利亚股份公司 2023-11-07 — — CN disclosed
US-20220259173-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF SPIROCHEM AG (CH) 2022-08-18 — — US disclosed
EP-3589390-B1 SELECTIVELY PERMEABLE GRAPHENE OXIDE MEMBRANE NITTO DENKO CORP (JP) 2022-08-17 — — EP disclosed
US-20210178336-A1 SELECTIVELY PERMEABLE GRAPHENE OXIDE MEMBRANE NITTO DENKO CORPORATION (JP) 2021-06-17 — — US disclosed
US-20200261861-A1 SELECTIVELY PERMEABLE GRAPHENE OXIDE MEMBRANE NITTO DENKO CORPORATION (JP) 2020-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240424006-A1 USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UBQLN2, SOD1, UBQLN1 KDM4E 4157/4885CYP1A2 4580/4885CYP2C19 4733/4885
US-12358884-B2 Urolithin derivatives and methods of use thereof NLN, UQCRC2, TUFM KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885
US-20240158364-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF NLN, UQCRC2, TUFM KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885
US-20240158363-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF NLN, UQCRC2, TUFM KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885
US-12351567-B2 Urolithin derivatives and methods of use thereof NLN, UQCRC2, TUFM KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885
US-20220259173-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF NLN, UQCRC2, TUFM KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885
US-20240158365-A1 UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF NLN, UQCRC2, TUFM KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885
US-12473269-B2 Urolithin derivatives and methods of use thereof NLN, UQCRC2, TUFM KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885
US-20240139149-A1 THERAPEUTIC USES OF UROLITHIN DERIVATIVES TNNT2, TNNI3, TNNC1 KDM4E 3913/4885CYP1A2 4808/4885CYP2C19 4876/4885
US-11820751-B2 Urolithin derivatives and methods of use thereof NLN, UQCRC2, TUFM KDM4E 4333/4885CYP1A2 4096/4885CYP2C19 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.